Skip to content

Study · Randomized controlled trial · n = 42 · 1992

6 results

Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial.

Penzias AS, Shamma FN, Gutmann JN, Jones EE, DeCherney AH, Lavy G

Obstetrics and gynecology1 May 1992Cited by 12 (Europe PMC)

PMID1533022 (opens in a new tab)PepBankPUB-01533022
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients undergoing their first IVF cycle, cycle cancellation did not differ significantly between nafarelin and leuprolide.

    In plain wordsIn patients undergoing their first IVF cycle, cycle cancellation did not differ significantly between nafarelin and leuprolide.

    Peptide
    Nafarelin
    Outcome
    No significant changeCycle cancellation
    Study

    n = 42

    Comparator
    Leuprolide acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Patient characteristics in the two groups did not differ significantly, nor did cycle cancellation rates or outcome.
    2 context sentences
    Summary · context
    We performed this study to compare patient response to intranasal nafarelin acetate versus subcutaneous leuprolide acetate as adjuncts to ovulation induction for in vitro fertilization (IVF).
    Summary · context
    Forty-two patients entering their first cycle of IVF were randomized to receive either nafarelin acetate or leuprolide acetate.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients undergoing their first IVF cycle, cycle outcome did not differ significantly between nafarelin and leuprolide.

    In plain wordsIn patients undergoing their first IVF cycle, cycle outcome did not differ significantly between nafarelin and leuprolide.

    Peptide
    Nafarelin
    Outcome
    No significant changeCycle outcome
    Study

    n = 42

    Comparator
    Leuprolide acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Patient characteristics in the two groups did not differ significantly, nor did cycle cancellation rates or outcome.
    2 context sentences
    Summary · context
    We performed this study to compare patient response to intranasal nafarelin acetate versus subcutaneous leuprolide acetate as adjuncts to ovulation induction for in vitro fertilization (IVF).
    Summary · context
    Forty-two patients entering their first cycle of IVF were randomized to receive either nafarelin acetate or leuprolide acetate.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients undergoing IVF, follicular estradiol, FSH and LH, luteal estradiol, and progesterone did not differ significantly between nafarelin and leuprolide.

    In plain wordsIn patients undergoing IVF, follicular and luteal hormone responses did not differ significantly between nafarelin and leuprolide.

    Peptide
    Nafarelin
    Outcome
    No significant changeFollicular and luteal hormone response
    Study

    n = 42

    Comparator
    Leuprolide acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference in patient response as indicated by follicular phase serum levels of estradiol (E2), FSH, or LH, luteal phase E2, and progesterone.
    2 context sentences
    Summary · context
    We performed this study to compare patient response to intranasal nafarelin acetate versus subcutaneous leuprolide acetate as adjuncts to ovulation induction for in vitro fertilization (IVF).
    Summary · context
    Forty-two patients entering their first cycle of IVF were randomized to receive either nafarelin acetate or leuprolide acetate.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients undergoing IVF, luteal progesterone-dependent endometrial protein was significantly lower with nafarelin than leuprolide but remained normal.

    In plain wordsIn patients undergoing IVF, an endometrial protein was lower with nafarelin than leuprolide but remained within the normal range.

    Peptide
    Nafarelin
    Outcome
    DecreaseLuteal progesterone-dependent endometrial protein
    Study

    n = 42

    Comparator
    Leuprolide acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Luteal phase progesterone-dependent endometrial protein was significantly lower in those taking nafarelin acetate, though it remained in the normal range.
    2 context sentences
    Summary · context
    We performed this study to compare patient response to intranasal nafarelin acetate versus subcutaneous leuprolide acetate as adjuncts to ovulation induction for in vitro fertilization (IVF).
    Summary · context
    Forty-two patients entering their first cycle of IVF were randomized to receive either nafarelin acetate or leuprolide acetate.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients undergoing IVF, nafarelin required significantly less hMG than leuprolide.

    In plain wordsIn patients undergoing IVF, nafarelin required significantly less hMG than leuprolide.

    Peptide
    Nafarelin
    Outcome
    DecreasehMG requirement
    Study

    n = 42

    Comparator
    Leuprolide acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    However, those receiving nafarelin acetate required significantly less human menopausal gonadotropin (hMG) and had significantly more embryos frozen for later transfer than those receiving leuprolide acetate.
    2 context sentences
    Summary · context
    We performed this study to compare patient response to intranasal nafarelin acetate versus subcutaneous leuprolide acetate as adjuncts to ovulation induction for in vitro fertilization (IVF).
    Summary · context
    Forty-two patients entering their first cycle of IVF were randomized to receive either nafarelin acetate or leuprolide acetate.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients undergoing IVF, significantly more embryos were frozen for later transfer with nafarelin than leuprolide.

    In plain wordsIn patients undergoing IVF, more embryos were frozen for later transfer with nafarelin than leuprolide.

    Peptide
    Nafarelin
    Outcome
    IncreaseEmbryos frozen
    Study

    n = 42

    Comparator
    Leuprolide acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    However, those receiving nafarelin acetate required significantly less human menopausal gonadotropin (hMG) and had significantly more embryos frozen for later transfer than those receiving leuprolide acetate.
    2 context sentences
    Summary · context
    We performed this study to compare patient response to intranasal nafarelin acetate versus subcutaneous leuprolide acetate as adjuncts to ovulation induction for in vitro fertilization (IVF).
    Summary · context
    Forty-two patients entering their first cycle of IVF were randomized to receive either nafarelin acetate or leuprolide acetate.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.